We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
- Authors
Currier, Jeffrey R; Ngauy, Viseth; de Souza, Mark S; Ratto-Kim, Silvia; Cox, Josephine H; Polonis, Victoria R; Earl, Patricia; Moss, Bernard; Peel, Sheila; Slike, Bonnie; Sriplienchan, Somchai; Thongcharoen, Prasert; Paris, Robert M; Robb, Merlin L; Kim, Jerome; Michael, Nelson L; Marovich, Mary A
- Abstract
We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol. The HIV sequences were derived from circulating recombinant form CRF01_AE, which predominates in Thailand. The objective was to evaluate safety and immunogenicity of MVA-CMDR in human volunteers in the US and Thailand.
- Publication
PloS one, 2010, Vol 5, Issue 11, pe13983
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0013983